Evidence map›Paper›PMID 39351230›Full record

ArticleFrontiers in immunology2024

Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium.

Kohei Togami, Whitney Wolf, Lucas C Olson, Madison Card, Limei Shen, Alison Schaefer, Kenichi Okuda, Larry Zeitlin, Michael Pauly, Kevin Whaley and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kohei TogamiDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Whitney WolfDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Lucas C OlsonDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Madison CardMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Limei ShenDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Alison SchaeferDepartment of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Kenichi OkudaMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Larry ZeitlinZabBio, San Diego, CA, United States.
Michael PaulyZabBio, San Diego, CA, United States.
Kevin WhaleyZabBio, San Diego, CA, United States.
Raymond J PicklesMarsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Samuel K LaiDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Scott H Randell · 2004 to 2026
$26.5M
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infectionsR01AI165853 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Samuel Lai, RAYMOND J PICKLES · 2022 to 2026
$3.1M
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPVR44AI157661 · NIAID · MUCOMMUNE, LLC · PI CONE, RICHARD · 2021 to 2024
$2.4M
NCI NIH HHS P30 CA016086NIAID NIH HHS R01 AI165853NIAID NIH HHS R44 AI157661NIDDK NIH HHS P30 DK065988
6 · The paper itself

Abstract

Effective treatment and immunoprophylaxis of viral respiratory infections with neutralizing monoclonal antibodies (mAbs) require maintaining inhibitory concentrations of mAbs at the airway surface. While engineered mAbs with increased affinity to the neonatal Fc receptor (FcRn) are increasingly employed, little is known how increased affinity of Fc to FcRn influences basal-to-apical transepithelial transport (transcytosis) of mAbs across the airway epithelium. To investigate this, we utilized a model of well-differentiated human airway epithelium (WD-HAE) that exhibited robust FcRn expression, and measured the transepithelial transport of a mAb against SARS-CoV-2 Spike protein (CR3022) with either wildtype IgG

Indexed as

Antibodies, MonoclonalHistocompatibility Antigens Class IImmunoglobulin GReceptors, FcRespiratory MucosaTranscytosisAntibodies, NeutralizingCOVID-19HumansSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin GReceptors, FcSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2airwayFcRnlungmonoclonal Absrespiratory virustranscytosis

Identifiers

PMID39351230
PMCPMC11439726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.